pharma · Esophageal Squamous Cell Carcinoma
Sichuan University
Sichuan University is a pharma organization headquartered in CN. Primary therapeutic focus areas include Esophageal Squamous Cell Carcinoma. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent rec
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 4
- Patents
- 0
PD-1 Inhibitor plus Chemotherapy
Phase 2 · small molecule · Esophageal Squamous Cell Carcinoma
PD-1 Inhibitor plus Chemotherapy for Esophageal Squamous Cell Carcinoma is a Phase 2 program (small_molecule) at Sichuan University with 1 ClinicalTrials.gov record(s).
Internal code 2026-191
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sichuan University
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Esophageal Squamous Cell Carcinoma
- Status
- active
- Trials
- 1